OLMA - NASDAQ

Olema Pharmaceuticals, Inc.

OLMA·NASDAQ

$10.51

-1.7%

HealthcareBiotechnology

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$918.02M

EPS-1.8700

P/E Ratio-5.62

Earnings Date08/10/2026

533.43M

Assets

18%

3Y+147.0%

5Y+56.0%

10Y+16208.0%

54.87M

Total Liabilities

31%

3Y+203.0%

5Y+1097.0%

10Y+475.0%

478.56M

Total Equity

17%

3Y+142.0%

5Y+42.0%

10Y-7723.0%

Olema Pharmaceuticals, Inc. Funding & Solvency Profile

OLMA · NASDAQ

Current Assets

Cash & Cash Equivalents48.30M

Net Receivables4.06M

Inventory0.00

Other Current Assets5.96M

Total Current Assets515 M

Non-Current Assets

Property, Plant & Equipment1.15M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets16.83M

Total Non-Current Assets18 M

Total Assets

533.43M

Financial Health Analysis

Current Ratio

9.95x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.11x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

464 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

97% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Olema Pharmaceuticals, Inc. Balance Sheet

OLMA • NASDAQ

Olema Pharmaceuticals, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	48.3M	139.5M	68.5M	23.7M	13.8M	338.5M	68K	3.1M
Short-Term Investments	457.1M	294.6M	193.3M	180.7M	273.4M	0.0	0.0	0.0
Cash & Short-Term Investments	505.4M	434.1M	261.8M	204.4M	287.3M	338.5M	68K	3.1M
Net Receivables	4.1M	2.1M	673K	319K	130K	0.0	0.0	0.0
Accounts Receivables	0.0	2.1M	0.0	319K	130K	0.0	0.0	0.0
Other Receivables	4.1M	0.0	673K	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	1.9M	2.4M	2.6M	3.3M	3M	0.0	0.0
Other Current Assets	6M	366K	1.7M	1.5M	0.0	581K	35K	93K
Total Current Assets	515.5M	438.5M	266.5M	208.9M	290.7M	342.1M	103K	3.2M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	1.1M	2.1M	3.3M	4M	4.7M	75K	26K	26K
Intangible Assets	0.0	683K	0.0	0.0	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	0.0	683K	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	16.8M	9.8M	7.2M	2.8M	540K	510K	3K	3K
Total Non-Current Assets	18M	12.5M	10.4M	6.7M	5.3M	585K	29K	29K
Total Assets	533.4M	451M	276.9M	215.6M	295.9M	342.7M	132K	3.3M
LIABILITIES
CURRENT LIABILITIES
Total Payables	9.3M	4.5M	2.8M	442K	111K	719K	935K	116K
Accounts Payable	9.3M	4.5M	2.7M	374K	23K	719K	935K	116K
Other Payables	0.0	41K	73K	68K	88K	0.0	0.0	0.0
Accrued Expenses	9.4M	36.1M	12.4M	10.5M	4M	3.4M	0.0	0.0
Short Term Debt	1.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	1.2M	988K	1M	931K	0.0	0.0	0.0
Tax Payables	0.0	41K	73K	68K	88K	642K	0.0	0.0
Other Current Liabilities	32M	0.0	5.5M	4.6M	4M	436K	443K	85K
Total Current Liabilities	51.8M	41.8M	21.6M	16.5M	9M	4.6M	1.4M	201K
NON-CURRENT LIABILITIES
Long Term Debt	69K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	3M	0.0	0.0	0.0	0.0	0.0	9.3M	9.3M
Total Non-Current Liabilities	3.1M	257K	1.4M	1.6M	2.4M	0.0	9.3M	9.3M
Capital Lease Obligations	0.0	1.4M	2.4M	2.6M	3.3M	0.0	0.0	0.0
Total Liabilities	54.9M	42M	23.1M	18.1M	11.4M	4.6M	10.7M	9.5M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	9.3M	9.3M
Common Stock	8K	6K	4K	3K	3K	3K	0.0	1K
Additional Paid-In Capital	0.0	843.9M	559.2M	408.3M	388.9M	371.2M	168K	167K
Retained Earnings	-597.6M	-435.1M	-305.6M	-209M	-104.2M	-33.1M	-10.8M	-6.4M
Accumulated Other Comprehensive Income/Loss	621K	143K	347K	-1.8M	-149K	0.0	-80K	-71K
Other Total Stockholders' Equity	1.1B	0.0	0.0	0.0	0.0	0.0	-9.3M	71K
Total Stockholders' Equity	478.6M	409M	253.9M	197.5M	284.6M	338.1M	-10.6M	-6.3M
Total Equity	478.6M	409M	253.9M	197.5M	284.6M	338.1M	-10.6M	-6.3M
SUMMARY
Total Liabilities & Equity	533.4M	451M	276.9M	215.6M	295.9M	342.7M	132K	3.3M
Total Investments	457.1M	294.6M	193.3M	180.7M	273.4M	0.0	0.0	0.0
Total Debt	1.2M	1.4M	2.4M	2.6M	3.3M	0.0	0.0	0.0
Net Debt	-47.1M	-138.1M	-66.1M	-21.1M	-10.5M	-338.5M	-68K	-3.1M
Shares Outstanding	68,634,329	68,634,329	68,634,329	68,634,329	68,634,329	68,634,329	68,634,329	68,634,329

SEC Filings

OLMA - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 26, 2026	May 26, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 21, 2026	May 21, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 12, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 12, 2026	May 12, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 01, 2026	April 27, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 29, 2026	April 29, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 29, 2026	April 27, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 16, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 16, 2026	March 16, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 30, 2026	January 27, 2026	2026	View Filing

Showing 1 to 10 of 96 filings

Related Guides

Blog Categories

Continue your OLMA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.